N/A N=57 Recommendations and Alerting for Delirium Alleviation in Real-Time (RADAR)
Delirium
Primary: Delirium — 3; 3; 1; 2 Participants — p=0.653
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,000 ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial
Radiation Exposure
Primary: Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator — 6.41; 3.51 10,000 x uSv / mGy*cm^2
N/A N=45 Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
Stage IV Non-Small Cell Lung Cancer
Primary: Progression-free Survival — 26 Participants — p=0.0007
N/A N=300 DIstal vs Proximal Radial Artery Access for Cath
Coronary Angiography · Coronary Angioplasty
Primary: Quick Disabilities of the Arm Shoulder and Hand (DASH) Questionnaire Score (0-100) — 0; 0 DASH Score change from baseline
N/A N=300 RAVE: Radial Artery Vascular Complication and Resource Utilization
Angiogram · Percutaneous Coronary Intervention
Primary: Time to Hemostasis — 19; 120; 44; 45 minutes
N/A N=26 Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)
Prostate Cancer · Prostate Adenocarcinoma · Radiation Toxicity
Primary: Number of Patients Who Experienced Early Toxicity of SBRT With Integrated Boost for Localized Prostate Cancer — 22 number of participants
N/A N=265 Physician Radiation Exposure During Radial Access Cardiac Catheterization Using a RAD Board
Radiation Exposure to Operator
Primary: Operator Radiation Exposure — .65; .56 mSv
N/A N=151 Evaluation of Safety and Efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System in the Treatment of Iliac and Femoropopliteal Lesions Via Transradial Access
Peripheral Arterial Disease
Primary: Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome) — 0 Participants
Phase 2 N=22 RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
Metastatic Melanoma
Primary: Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
N/A N=64 RADAR Clinical Trial
Persistent Atrial Fibrillation
Primary: Number of Participants With Atrial Fibrillation Termination — 23; 12 Participants
N/A N=170 Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation
Cardiac Catheterization · Radiation Exposure
Primary: Radiation Dose to Primary Operator (RaySafe), Cardiac Catheterization — 18; 39 microsievert
Phase 2 N=64 RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
Prostate Cancer
Primary: Progression-free Survival — 10.5; 11.8 Months
Phase 2 N=22 A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Prostate Cancer · Castration-resistant Prostate Cancer · Castration-resistant Prostate Cancer Metastatic to Bone
Primary: Bone Scan Index — 2.90; 3.79 percentage of skeletal mass
Phase 2 N=71 Treatment of Patients With RAD001 With Progressive Sarcoma
Progressive Sarcoma
Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1
N/A N=698 Radial Artery Access With Ultrasound Trial
Coronary Artery Disease
Primary: Number of Attempts — 3.05; 1.65 forward attempts — p=<0.0001
Phase 2 N=28 RAD001 in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC). — 10 mg — p=0.05
Phase 4 N=1,962 RIGHT: Rhythm ID Going Head-to-Head Trial
Tachycardia
Primary: Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge…
Phase 3 N=806 Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Prostatic Neoplasms
Primary: Symptomatic Skeletal Event Free Survival (SSE-FS) — 22.3; 26.0 Months — p=0.2636
Phase 1 N=100 Regadenoson R-T Perfusion Imaging Trial
Coronary Artery Disease · Myocardial Perfusion Abnormalities
Primary: Detection of Coronary Artery Disease With Real-time Perfusion Echocardiography During Regadenoson Stress — 98; 98 Participants — p=<0.001
Phase 2 N=52 Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
Prostate Cancer
Primary: Assess the Efficacy of Radium-223 in Terms of Radiological rPFS — 5.53 months
N/A N=25 Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
Prostate Cancer
Primary: Overall Survival (Favorable and Unfavorable ) — 13.9; 36.3 months
Phase 2 N=187 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
Phase 2 N=29 Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Metastatic Prostate Cancer · Pain
Primary: Percentage of Participants With 30% Decline in the Brief Pain Inventory (BPI) Worst Pain Item From Baseline to Week 8 — 11 Percentage of pts w/pain improvement
N/A N=1,472 Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Participants With Second Primary Malignancies (SPM) — 24 Participants
Phase 3 N=742 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
Phase 1 N=59 RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
Metastatic Cancers
Primary: Number of Adverse Events — 428 Adverse Events
Phase 4 N=20 DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
Peripheral Arterial Disease
Primary: Overall Image Quality of MRA Images — 56; 48 Images
N/A N=184 Real-World Outcomes Study on Subjects Treated With Radiofrequency Ablation
Pain
Primary: Primary Effectiveness Endpoint: Relative Change in Numeric Rating Scale (NRS) From Baseline to 3 Months Follow-up Visit — 34.4 score on a scale — p=< 0.0001
Phase 4 N=108 Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: Reliability of the European League Against Rheumatism - Rheumatism Arthritis Impact of Disease (EULAR-RAID) Score — 0.85 intraclass correlation coefficient — p=0.000
Phase 2 N=391 Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Prostatic Neoplasms
Primary: Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose — 85; 118 Participants